PORTLAND, Oregon, April 14, 2016 /PRNewswire/ --
According to a new report by Allied Market Research, titled, "World IV Ibuprofen Market-Opportunities and Forecasts, 2015-2022," the global intravenous (IV) ibuprofen market is projected to reach $14.2 million by 2022. The pain indication segment accounted for over three-fourths share in 2015 and is expected to maintain its dominance throughout the forecast period.
(Logo: http://photos.prnewswire.com/prnh/20140911/647229 )
To know more about the report, visit the website at https://www.alliedmarketresearch.com/intravenous-ibuprofen-market
The major factors that boost the market growth include, increase in adoption of intravenous mode of drug delivery for acute pain management due to faster onset of action as compared to the other routes (oral and transdermal mode of administration) and targeted drug delivery property. The market growth is further augmented as IV ibuprofen improves pain management with less dependence on opioid analgesic medication, which may lead to several health complications such as sedation, dizziness, and others. Caldolor (Cumberland Pharmaceuticals) is the only injectable ibuprofen drug available in the market; hence, it has huge demand with minimal competition. However, numerous factors are likely to restrain the market growth such as lengthy approval process and limited geographic (country specific) approvals. The IV Ibuprofen market is estimated to grow at a CAGR of 20.0% during 2016 and 2022.
Adults end user segment accounted for major share in 2015, and is projected to maintain this trend throughout the forecast period. This is because the IV Ibuprofen was not prescribed for pediatrics until 2014. Pediatrics is projected to be the fastest growing end user segment, owing to the growing need for rapid pain and fever management in children (to avoid damage caused by inflammation and high body temperature) and increasing awareness about the use of IV Ibuprofen in children.
Key Findings:
The U.S. is anticipated to remain the highest revenue-generating region during the forecast period, owing to the widespread adoption of IV Ibuprofen for treating pain and fever. However, Australia is expected to grow rapidly during the forecast period, owing to recent entry of IV Ibuprofen in this market, increasing awareness of non-steroidal anti-inflammatory drugs, and shifting trend towards intravenous mode of drug delivery.
The IV Ibuprofen market is dominated by Cumberland Pharmaceuticals and is actively engaged in research for the development of novel IV Ibuprofen products. The key ibuprofen companies profiled in this report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc. (Acquired by Teligent, Inc.), CSL Limited, Sandor Medicaids Pvt. Ltd., PT. Soho Industri Pharmasi, Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., and Laboratorios Valmorca, C.A.
Similar reports published by Allied Market Research -
World Anti-Inflammatory Therapeutics Market - The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs.
To know more about the anti-inflammatory therapeutics market report, visit the website at https://www.alliedmarketresearch.com/anti-inflammatory-therapeutics-market
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
Sona Padmanabhan
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Int'l: +1-503-894-6022
Toll Free: + 1-800-792-5285 (U.S. & Canada)
E-mail: sales@alliedmarketresearch.com
Share this article